GAMMA Investing
BCAX icon

GAMMA Investing’s Bicara Therapeutics BCAX Stock Holding History

GAMMA Investing’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.7K Buy
1,491
+26
+2% +$651 ﹤0.01% 2742
2026
Q2 		$43.5K Buy
1,465
+65
+5% +$1.45K ﹤0.01% 2394
2026
Q1 		$27.8K Buy
1,400
+275
+24% +$4.73K ﹤0.01% 2538
2025
Q4 		$18.9K Sell
1,125
-11
-1% -$188 ﹤0.01% 2649
2025
Q3 		$17.9K Buy
1,136
+459
+68% +$5.14K ﹤0.01% 2571
2025
Q2 		$6.29K Buy
677
+82
+14% +$977 ﹤0.01% 3027
2025
Q1 		$7.75K Buy
595
+536
+908% +$7.12K ﹤0.01% 2870
2024
Q4 		$1.03K Buy
+59
New +$1.23K ﹤0.01% 3418

Other funds holding BCAX

RTM
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Private Trust Company
Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's BCAX Position: Q3 2026 in Review

GAMMA Investing increased its Bicara Therapeutics (BCAX) stake by 1.8% in Q3 2026, buying an estimated $651 and bringing the position to 1,491 shares worth $27.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

GAMMA Investing first reported a position in BCAX in Q4 2024 and has held it in 8 quarters since. The position peaked at $43.5K in Q2 2026. 9 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • GAMMA Investing held 1,491 shares of Bicara Therapeutics worth $27.7K as of Q3 2026.
  • GAMMA Investing bought 26 Bicara Therapeutics shares in Q3 2026, an estimated $651.
  • Bicara Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2742 holding.
  • GAMMA Investing first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • GAMMA Investing's Bicara Therapeutics position peaked at $43.5K in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.